InteliSpark is now an approved SBIR/STTR service provider for Pennsylvania's Innovation Partnership

We are excited to announce that InteliSpark has recently become an approved SBIR/STTR service provider for Pennsylvania's Innovation Partnership.  The Innovation Partnership is a consortium of economic development and business assistance organizations located throughout the Commonwealth of Pennsylvania. Their goal is to help early-stage technology companies in Pennsylvania secure federal funding opportunities.

The Innovation Partnership Preferred Provider (PP) Listing is offered as a courtesy to IPart, SBIR/STTR and federal funding assistance clients who are seeking the help of experienced grant-writing professionals. The listing gives a brief description of the products and services which might be offered by the provider to clients as well as their technology focus/federal agency experience or specialization areas.

Pre-Proposal Assistance Program

Financial Support for Grant Preparation in the form ofawards of up to $3,000 for Phase I SBIR/STTR proposal preparation and up to $10,000 for Phase II

DexMat Wins Phase II NASA Contract

InteliSpark client Dexmat has won a $750k contract with NASA for the Phase II Small Business Innovation Research (SBIR) project, "Lightweight CNT Shielded Cables for Space Applications."

DexMat manufactures high performance products made from Carbon Nanotubes (CNTs) for a new generation of consumer and commercial applications. They developed a novel CNT deposition process for directly applying CNTs onto dielectric materials to produce an electrically conductive EMI shield. By placing a premium on the quality of raw CNTs, DexMat has created a product with increased potential to reduce cable weight while minimizing insertion losses when incorporated into wire.

Lightweight CNT shielded cables would provide a significant cost-effectiveness by reducing weight in space applications. DexMat technology offers a significant weight reduction, up to 80%, in these wires resulting in a noteworthy cost savings for launched vehicles. Given the tremendous costs associated with satellite launches, the NASA will see significant savings from our CNT-based wire.

After showing successful integration into the aviation manufacturing industry, DexMat plans to expand CNTs into the textile, sensors and medical devices, electronics, energy storage and structural industries. CNTs offer significant improvements to existing technologies in these industries and could outperform current state-of-the-art products on the market.

WntRx wins Phase I NIH STTR grant

InteliSpark client WntRx has been awarded a National Institutes of Health (NIH) Phase I Small Business Technology Transfer (STTR) grant worth $225,000 funded by the National Cancer Institute. The grant is for the STTR project, "Investigation of Antibody-Drug Conjugates of a Novel Target." This will enable WntRx to compete for a NIH Phase II STTR award.

WntRx Pharmaceuticals Inc. is building on the promise of Wnt signaling by applying its unique capabilities to discover and develop non-toxic, selective drugs for the treatment of patients with critical unmet medical needs. The company focuses on the development of novel, safe, selective, oncogenic specific inhibitors of Wnt signaling active in the treatment of cancer.

Antibody–drug conjugates (ADCs) are monoclonal antibodies (mAbs) that are covalently linked to cell-killing drugs and have emerged as a major modality in anti-cancer treatment. As antibody engineering and linker-payload optimization are becoming mature, the discovery and development of new ADCs is increasingly dependent on the identification and validation of new targets that are suitable to this approach.

 LGR4 (leucine-rich repeat containing, G protein-coupled receptor 4) is a seven transmembrane domain receptor that is highly upregulated expression in the majority of solid tumors, including colorectal, lung, and ovarian cancers. LGR4 functions as a receptor of the R-spondin group of stem cell factors to potentiate Wnt signaling.

WntRX has generated and characterized a panel of highly potent and specific mAbs against native LGR4. Preliminary data showed that LGR4 mAbs conjugated with a potent cytotoxin were able to inhibit the growth of several cancer cell lines with high LGR4 expression in vitro and tumor xenografts in vivo. Here we propose to determine the potency, efficacy, and therapeutic window of anti-LGR4 ADCs in xenograft models of patient-derived tumors to establish proof-of-principle for the use of LGR4-targeded ADCs for the treatment of LGR4-high tumors. These results and conclusions may, for the first time, validate LGR4 as a novel target for the development of ADC-based therapeutics that has the potential to treat a large population of cancer patients.

ArhcieMD, Inc. wins Phase I DHA STTR Contract

InteliSpark client ArchieMD, Inc. has been awarded a Defense Health Agency (DHA) Phase I Small Business Technology Transfer (STTR) contract worth $149,993. The grant is for the STTR project “Dynamic Virtual Moulage Base on Thin Film Adhesive Displays.”

The goal of the STTR project is to provide Army combat medics with a meaningful experience in treating injuries obtained on the battlefield during particular challenges. Moulage has great potential to aid in acquiring preparatory experience for distressing real life emergencies that medics and soldiers encounter in the field. The current approach to moulage is limited in the ability to reflect the impact of treatment decisions the trainee makes during the simulation.

This is where ArchieMD proposed to develop a dynamic moulage technology with the ability to morph to reflect changes in medical simulation scenarios. A very think and flexible electronic sticker that adheres to the skin will show a variety of dynamic information, including vital signs, disease progression and response to treatment or treatment error to provide the trainee with information about clinical progression and changes in the physiological state of the simulated patient. This could potentially lead to improvements in critical thinking, assessment and response time.

ArchieMD’s technology can be easily attached to and removed from mannequins, simulated proxy body parts, or real persons, allowing integration with existing simulation systems. It could also be commercialized to benefit EMS and other first responders undergoing training simulations.

SensoDX NIDCR SBIR Fast Track Project advances to Phase II

InteliSpark client SensoDX II LLC  awarded the Phase II portion of a National Institute of Dental & Craniofacial Research Fast Track Small Business Innovation Research (SBIR) . The grant is for the SBIR project “Lab-on-a-Chip-Based System for Detection and Monitoring of Oral Cancer in Dental Settings.” SensoDX II focuses on creating state-of-the-art multi-parameter point-of-care diagnostic solutions that provide test information directly to patients and healthcare providers through intuitive mobile health interfaces.

Oral cavity and pharynx cancers are among the most serious cancers. There are about 400,000 incidents globally. In the U.S., the 5-year survival rate is about 64% among the lowest for all forms of cancer. When diagnosed during an early stage, the survival rate increases dramatically to 83%. However, oral cavity and pharynx cancers are among the most expensive cancers to treat due to the fact that most cases are advanced at the time of diagnoses.

Under the SBIR project, SensoDX fast Track application seeks to shift the current clinical practice paradigm for screening and diagnosis of potentially malignant oral lesions by moving away from the sole reliance on invasive scalpel biopsies followed by expensive and time consuming pathology exams to a new paradigm whereby noninvasive brush biopsies are combined with a state-of-the-art `cytology-on-a-chip' system for on the spot analysis of samples. This new technology will afford for the first-time single cell analysis of cytology specimens at the point-of-care. These powerful chip-based tools, along with new diagnostic models, have strong promise to improve the way screening and diagnosis of oral cancer is completed on a global basis.

The SensoDX OraTechTM sampling device and integrated OraTechTM cartridge together are projected to form the first effective adjunctive diagnostic aid capable of management of malignant and potentially malignant oral lesions on a rapid time frame with high sensitivity and high specificity. Diagnostic models based on biomarker data derived from these powerful chip-based tools, alongside lesion characteristics obtained from a customized mHealth App will allow for an elegant data fusion process to occur whereby lesion characteristics, risk factors and the numerous cytology factors yield the desperately needed clinical insights for patients suffering from oral cancer.

In second major phase, the consumables will be scaled, manufacturing processes will be developed and the instrumentation and cartridges will be validated using banked specimens.

Click here to learn more!

Shasqi wins Phase II NSF SBIR grant

InteliSpark client Shasqi, Inc. has been awarded a National Science Foundation (NSF) Phase II Small Business Innovation Research (SBIR) grant worth $749,906. The grant is for the SBIR project “Biomaterials and Chemistry to Enhance the Delivery of Medicines in the Body.” Shasqi, Inc. is a company that has created a new technology to deliver drugs to specific areas in the body. 

The goal of the SBIR project is to improve a new technology to deliver medicine to specific parts of the body. Local medical problems are issues that affect only one specific part of the body such as your knee. These issues are regularly treated with medicines that spread throughout the entire body and only a small portion actually reaches where it needs to. A medication that reaches its intended target would be ideal. Unfortunately, the majority of medications in the market are not ideal.

Under the SBIR project, Shasqi, Inc. is working on a drug delivery technology allowing implantable material to mark a particular spot of the body where a procedure was done. The drug lasts for a few weeks and allows for the medication a patient is taking to concentrate and activate at the specific area of the body where the drug was implanted instead of all over the body.

The project will determine the Shasqi, Inc. ability to release different drug payloads in vitro and in vivo. These advances will improve drug approval rates, reduce the cost of drug development and bring medicine closer to the ideal medication for local medical problems.

Click here to learn more!

Pulmokine wins $515K Phase I NIH SBIR grant

Pulmokine, Inc. has been awarded a National Institute of Health Phase I Small Business Innovation Research (SBIR)  grant worth $515,000 entitled “A Phosphopeptide Multiplex PRM Mass Spectroscopic Biomarker Assay For PAH” . Pulmokine, Inc. is a privately held biopharmaceutical company focusing on pulmonary disease and kinase inhibitor technology. The company’s mission is to develop new ways of treating hard-to-treat lung conditions and pulmonary arterial hypertension (PAH) and related disorders.

 

The grant Pulmokine, Inc. has been awarded is for the SBIR project to develop a quantitative phosphopeptide biomarker assay for pulmonary arterial hypertension (PAH). It will consist of a kit of stable isotopically labeled internal standards of a selected set of phosphopeptides either up or down-regulated in PAH. The set of stable isotopically labeled peptides will be used to quantify the level of target phosphoproteins in the buffy coat fraction of blood in a parallel reaction monitoring (PRM) mass spectroscopy (MS) assay.

 

The company proposes to determine if a subset of these phosphoproteins are differentially regulated in peripheral blood mononuclear cells (PBMCs) (buffy coat, which contains lymphocytes and platelets) of subjects with PAH compared to controls, to develop assays that can be used to determine how the levels of these phosphoproteins change over time, and to determine if these levels correlate with clinically important endpoints: i.e., mortality risk, hospitalization for PAH, and listing for lung transplant.

 

Phase 2 of the project will address regulatory requirements for kit commercialization, provide a longer validation study, and perform serial sampling of subjects with iPAH to correlate biomarker results with clinical course and prognosis.

Click here for more information!

InteliSpark has an open position for an Entry-Level Proposal Development Coordinator

Position: Proposal Development Coordinator

Hours Per Week: Full-Time

Pay: BOE, salary

 Position Overview: The primary role for this position is to provide support for the InteliSpark, LLC (formerly Centurion Technology) team and clients in proposal development and submission. The position is well suited for a new or recent graduate.  Specific activities include:

  • Populating federal contract and grant application forms for agencies including NIH, NSF, DoD, DoE, and others

  • Tracking application status and required documents

  • Composition of short technical documents, including commercialization documents

  • Communicating with clients for company onboarding and government registrations

  • Additional support activities

Qualifications: Applicants must meet the following specifications:

  • Bachelor’s degree in business-related field or equivalent experience in grant management and writing

  • Proficiency in communication, written and oral, skills

  • Proficiency in Microsoft Suite (e.g., Word, Excel), Adobe Acrobat, Outlook

  • Ability to provide attention to detail

  • Ability to work independently and demonstrate self-management

       Preferred Qualifications:

  • Experience with EndNote and Google Spreadsheets

  • Experience with project management

  • Previous experience with federal contract and grant applications to agencies including: NIH, NSF, DoD, DoE, and others

About the Company: InteliSpark, LLC is a hands-on business development consulting firm specializing in securing non-dilutive funding for start-ups through the Small Business Innovative Research (SBIR), Small Business Technology Transfer (STTR), and other government research funding programs.  We work with start-ups, universities, venture capital firms and economic development programs to match small innovative companies and technologies with funding opportunities. Using our proven track record of creating winning SBIR/STTR proposals, we turn those opportunities into realities. 

To Apply: Please send resume and cover letter to Kirk Macolini at kirk@intelispark.com

Sample 6 Technologies wins NIAID (NIH) Phase II SBIR grant

InteliSpark client Sample6 Technologies has been awarded a $1 million Phase II SBIR grant from the National Institute of Allergy and Infectious Diseases (NIAID). The award is for the project “Adaptation Of An Enrichment-Free Listeria Diagnostic To Food Matrices” Sample6 is a company who is dedicated to revolutionize food safety through science, software and passion. The company shifts food safety from reaction to prevention through the use of in-shift pathogen diagnostics paired with powerful analytics. The tools they create are delivered to food processors, retailers and consumers.

Millions of Americans are effected by foodborne illness each year. The illness impact the gastrointestinal microflora resulting in dysbiosis and increasing the risk of other illnesses such as namely irritable bowel syndrome, kidney failure, pancreatitis and diabetes. In fact, diabetics are at an increased risk of developing foodborne illness to begin with and take longer to recover. In 2014 there were 19,542 laboratory confirmed infections, 4,445 hospitalizations and 71 deaths from foodborne illness.

The cause of these illnesses is due to contaminated food that enter the public supply due to lack of detection at the manufacturing/packaging plant, distribution warehouse or retail location. The current tests are ineffective because they require a prolonged enrichment step to decrease the likelihood of false negatives and false positives. This causes a delay in providing actionable results to the food processor leaving them with two choices. They can either store the products for longer until they get the test results back, resulting in older, lower-quality food or sending the products out to the public before receiving the test results putting the public at risk of food contamination.

Under the SBIR project, Sample6 is developing the world’s first enrichment-free foodborne pathogen detection system. DETECT/L is a rapid screening that will detect single Listeria spp. cell in less than seven hours. Sample6’s exclusive Bioillumination platform will allow for speedy turnaround enabling food manufacturers and packagers to quickly detect any contamination and solely retain the products at risk.

However, food can become contaminated later on in the supply chain during production, shipping, or in wholesale and retail environments. It is important to develop a second test to prevent this. The Phase II study will continue the work begun in Phase I to adapt the DETECT/L for finished product testing.

Click here to learn more!

 

 

Rayonix wins DoE Phase I SBIR grant

InteliSpark client Rayonix has been awarded a Department of Energy Phase I SBIR grant. The grant is for the SBIR project “Development and Commercialization of a Novel Two-Color Hybrid Pixel X-Ray Detector”.  Rayonix builds the most advanced large area X-ray detectors on the market. These detectors allow scientists to make strides while researching a number of different scientific fields.

Under the SBIR project, Rayonix will develop and commercialize a fast-new hybrid pixel array detector for use at synchrotron facilities. This new X-ray detector, is referred to as the cPix2. It offers significant novel properties: the ability to record two simultaneous X-ray images at different colors or sample times, and the ability to accurately measure much more intense X-rays than previously possible. The cPix2, has capabilities that are currently not available on the market, such as sync mode for high photon count rate capability, and the ability to produce two full-resolution images per X-ray exposure.

ASIC 48x48 pixel prototype design is completed and physical devices will be available before this grant begins. Standardized Si sensors are available to be bump bonded and SLAC collaborators have the expertise and equipment to accomplish this during Phase I. SLAC is also able to build a first complete camera with readout electronics and computer interface card. At this point the cPix2 will be characterized with X-rays. Software development to produce a Linux driver, user interface and calibration tools, is to be completed by Rayonix. Computer hardware will also be provided by Rayonix and integrated with the new X-ray detector, to produce a complete system that can easily be transported to any synchrotron.

Several scientists and institutions have not only expressed support for this project but are ready to aid in the actual experiments to reach this goal. The cPix2 will be commercially available worldwide which will benefit many different material science research and industry fields and many new classes of experiments, such as pump-probe X-ray scattering, X-ray fluorescence, and time-resolved X-ray spectroscopy, leading to advances in materials research and life sciences.